Sai Praneeth Bathena

Associate Director, Clinical Pharmacology
Bristol Myers Squibb

Poster(s):

• (M-008) Exposure-Response Analysis of Efficacy and Safety for Nivolumab + Relatlimab Fixed-dose Combination (FDC) to Support Dose Justification in Patients with Unresectable or Metastatic Melanoma
  Monday, October 20, 2025

  7:00 AM - 5:00 PM MDT